Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: A population-based study from Northern Italy

Leukemia and Lymphoma

Volumn 52, Issue 9, 2011, Pages 1689-1696

  Luminari, Stefano ^a   Cesaretti, Marina ^a   Tomasello, Chiara ^a   Guida, Annalisa ^a   Bagni, Bruno ^a   Merli, Francesco ^b   Postiglione, Raffaella ^a   Mangone, Lucia ^c   Versari, Annibale ^b   Re, Francesca ^d   Lisi, Vincenzo De ^e   Ruffini, Livia ^d   Ferretti, Stefano ^f   Cuneo, Antonio ^f   Federico, Massimo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UO Pneumologia   (Italy)

^c AUSL di Reggio Emilia   (Italy)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

^e Registro Tumori Provincia Parma   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

Author keywords

cancer registry; FDG PET; Hodgkin lymphoma; population based study; prognostic factor; survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HODGKIN DISEASE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; ADOLESCENT; CANCER STAGING; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; SCINTISCANNING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052076652     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.580475     Document Type: Article

References (17)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.
2. Donaldson SS, Hancock SL, Hoppe RT. The Janeway lecture. Hodgkin's disease-finding the balance between cure and late effects. Cancer J Sci Am 1999;5:325-333. (Pubitemid 30022422)
3. Eghbali H, Raemaekers J, Carde P. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol Suppl 2005;(66):135-140. (Pubitemid 40873991)
4. Brepoels L, Stroobants S, Verhoef G. PET and PET/CT for response evaluation in lymphoma: current practice and developments. Leuk Lymphoma 2007;48:270-282. (Pubitemid 46994876)
5. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007;110:3507-3516. (Pubitemid 350159614)
6. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25: 579-586. (Pubitemid 350002966)
7. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107: 52-59. (Pubitemid 43053523)
8. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475-481.
9. Parkin DM, Plummer M. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 2002;8: 57-73.
10. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000;36:69-86.
11. Fritz A, Percy C, Jack A, et al., editors. International Classification of Diseases for Oncology. 3rd ed. Geneva: WHO; 2000.
12. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104: 1258-1265. (Pubitemid 39166497)
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
14. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med 2002;21: 2409-2419.
15. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174. (Pubitemid 8054849)
16. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-3752. (Pubitemid 47372616)
17. Rigacci L, Zinzani P, Puccini B, et al. Early FDG-PET scan confirms its prognostic impact also in localized stage, ABVD treated Hodgkin lymphoma patients. Haematologica 2010;95(Suppl. 4). Abstract C046.